NRL, 4th Floor Healy Building, 41 Victoria Parade, Fitzroy 3065, Australia.
BMC Infect Dis. 2014 Jun 12;14:325. doi: 10.1186/1471-2334-14-325.
Chlamydial infection is the most common notifiable disease in Australia, Europe and the US. Australian notifications of chlamydia rose four-fold from 20,274 cases in 2002 to 80,846 cases in 2011; the majority of cases were among young people aged less than 29 years. Along with test positivity rates, an understanding of the number of tests performed and the demographics of individuals being tested are key epidemiological indicators. The ACCESS Laboratory Network was established in 2008 to address this issue.
The ACCESS Laboratory Network collected chlamydia testing data from 15 laboratories around Australia over a three-year period using data extraction software. All chlamydia testing data from participating laboratories were extracted from the laboratory information system; patient identifiers converted to a unique, non-reversible code and de-identified data sent to a single database. Analysis of data by anatomical site included all specimens, but in age and sex specific analysis, only one testing episode was counted.
From 2008 to 2010 a total of 628,295 chlamydia tests were referred to the 15 laboratories. Of the 592,626 individual episodes presenting for testing, 70% were from female and 30% from male patients. In female patients, chlamydia positivity rate was 6.4% overall; the highest rate in 14 year olds (14.3%). In male patients, the chlamydia positivity rate was 9.4% overall; the highest in 19 year olds (16.5%). The most common sample type was urine (57%). In 3.2% of testing episodes, multiple anatomical sites were sampled. Urethral swabs gave the highest positivity rate for all anatomical sites in both female (7.7%) and male patients (14%), followed by urine (7.6% and 9.4%, respectively) and eye (6.3% and 7.9%, respectively).
The ACCESS Laboratory Network data are unique in both number and scope and are representative of chlamydia testing in both general practice and high-risk clinics. The findings from these data highlight much lower levels of testing in young people aged 20 years or less; in particular female patients aged less than 16 years, despite being the group with the highest positivity rate. Strategies are needed to increase the uptake of testing in this high-risk group.
衣原体感染是澳大利亚、欧洲和美国最常见的应报告疾病。澳大利亚衣原体报告病例从 2002 年的 20274 例增加到 2011 年的 80846 例,增加了四倍;大多数病例发生在年龄小于 29 岁的年轻人中。除了检测阳性率外,了解进行的检测数量和接受检测个体的人口统计学特征是关键的流行病学指标。ACCESS 实验室网络于 2008 年成立,旨在解决这一问题。
ACCESS 实验室网络使用数据提取软件从澳大利亚的 15 个实验室收集了三年期间的衣原体检测数据。所有参与实验室的衣原体检测数据均从实验室信息系统中提取;患者标识符转换为唯一的、不可逆的代码,并将去识别数据发送到一个单独的数据库。对解剖部位的数据分析包括所有标本,但在年龄和性别特定分析中,只计算一次检测事件。
2008 年至 2010 年,共有 628295 例衣原体检测样本被送到这 15 个实验室。在 592626 例接受检测的个体病例中,70%为女性患者,30%为男性患者。在女性患者中,衣原体阳性率总体为 6.4%;14 岁患者的阳性率最高(14.3%)。在男性患者中,衣原体阳性率总体为 9.4%;19 岁患者的阳性率最高(16.5%)。最常见的样本类型是尿液(57%)。在 3.2%的检测事件中,多个解剖部位进行了采样。在所有解剖部位中,尿道拭子对女性(7.7%)和男性患者(14%)的阳性率最高,其次是尿液(分别为 7.6%和 9.4%)和眼部(分别为 6.3%和 7.9%)。
ACCESS 实验室网络的数据在数量和范围上都是独一无二的,代表了普通诊所和高风险诊所的衣原体检测情况。这些数据的结果表明,20 岁或以下的年轻人,特别是年龄小于 16 岁的女性患者,检测率较低,尽管她们的阳性率最高。需要采取策略来增加这一高风险群体的检测率。